ESTER COMPOUND AND PHARMACEUTICAL USE OF THE SAME
PROBLEM TO BE SOLVED: To provide a hyperlipemia treating agent capable of inhibiting selectively a microsomal triglyceride transfer protein (MTP) in the small bowel, without acting substantially on the MTP in the liver, nor producing an adverse effect, such as fatty liver. SOLUTION: An ester compoun...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | TANIGUCHI HISAO HAGIWARA ATSUSHI MADONO KIYONARI OE YASUHIRO WATANABE SHIZUE IKENOUE HIROSHI KAWAI TAKASHI KOTANI NAOYA |
| description | PROBLEM TO BE SOLVED: To provide a hyperlipemia treating agent capable of inhibiting selectively a microsomal triglyceride transfer protein (MTP) in the small bowel, without acting substantially on the MTP in the liver, nor producing an adverse effect, such as fatty liver. SOLUTION: An ester compound expressed by general formula (1') [R2', R2"are each H, a 1-6C (halo)alkyl, a 1-6C alkoxy, a 1-6C acyl, a 3-7C cycloalkyl, a halogen, a 2-6C alkenyl or cyano; X1is -O- or NR10-(R10is H, a 1-6C alkyl or a 3-7C cycloalkyl); R1, R3, R4, R5, R6, R7, R8, R9, ring C, l and m are each defined in the specification, provided that a case in which ring C is a 6-14C aryl, a heterocyclic or a 3-7C cycloaryl, and R8and R9are each -CON(R18)(R19) (R18and R19are each defined in the specification) or -COO(R20) (R20is defined in the specification) is not included] or its pharmaceutically acceptable salt is provided. COPYRIGHT: (C)2005,JPO&NCIPI |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2005220133A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2005220133A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2005220133A3</originalsourceid><addsrcrecordid>eNrjZDB0DQ5xDVJw9vcN8A_1c1FwBOIAD8cgX0dn19AQT2dHH4XQYFcFfzeFEA9XhWBHX1ceBta0xJziVF4ozc2g5OYa4uyhm1qQH59aXJCYnJqXWhLvFWBkYGBqZGRgaGzsaEyUIgCAQCaX</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ESTER COMPOUND AND PHARMACEUTICAL USE OF THE SAME</title><source>esp@cenet</source><creator>TANIGUCHI HISAO ; HAGIWARA ATSUSHI ; MADONO KIYONARI ; OE YASUHIRO ; WATANABE SHIZUE ; IKENOUE HIROSHI ; KAWAI TAKASHI ; KOTANI NAOYA</creator><creatorcontrib>TANIGUCHI HISAO ; HAGIWARA ATSUSHI ; MADONO KIYONARI ; OE YASUHIRO ; WATANABE SHIZUE ; IKENOUE HIROSHI ; KAWAI TAKASHI ; KOTANI NAOYA</creatorcontrib><description>PROBLEM TO BE SOLVED: To provide a hyperlipemia treating agent capable of inhibiting selectively a microsomal triglyceride transfer protein (MTP) in the small bowel, without acting substantially on the MTP in the liver, nor producing an adverse effect, such as fatty liver. SOLUTION: An ester compound expressed by general formula (1') [R2', R2"are each H, a 1-6C (halo)alkyl, a 1-6C alkoxy, a 1-6C acyl, a 3-7C cycloalkyl, a halogen, a 2-6C alkenyl or cyano; X1is -O- or NR10-(R10is H, a 1-6C alkyl or a 3-7C cycloalkyl); R1, R3, R4, R5, R6, R7, R8, R9, ring C, l and m are each defined in the specification, provided that a case in which ring C is a 6-14C aryl, a heterocyclic or a 3-7C cycloaryl, and R8and R9are each -CON(R18)(R19) (R18and R19are each defined in the specification) or -COO(R20) (R20is defined in the specification) is not included] or its pharmaceutically acceptable salt is provided. COPYRIGHT: (C)2005,JPO&NCIPI</description><edition>7</edition><language>eng</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2005</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20050818&DB=EPODOC&CC=JP&NR=2005220133A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20050818&DB=EPODOC&CC=JP&NR=2005220133A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TANIGUCHI HISAO</creatorcontrib><creatorcontrib>HAGIWARA ATSUSHI</creatorcontrib><creatorcontrib>MADONO KIYONARI</creatorcontrib><creatorcontrib>OE YASUHIRO</creatorcontrib><creatorcontrib>WATANABE SHIZUE</creatorcontrib><creatorcontrib>IKENOUE HIROSHI</creatorcontrib><creatorcontrib>KAWAI TAKASHI</creatorcontrib><creatorcontrib>KOTANI NAOYA</creatorcontrib><title>ESTER COMPOUND AND PHARMACEUTICAL USE OF THE SAME</title><description>PROBLEM TO BE SOLVED: To provide a hyperlipemia treating agent capable of inhibiting selectively a microsomal triglyceride transfer protein (MTP) in the small bowel, without acting substantially on the MTP in the liver, nor producing an adverse effect, such as fatty liver. SOLUTION: An ester compound expressed by general formula (1') [R2', R2"are each H, a 1-6C (halo)alkyl, a 1-6C alkoxy, a 1-6C acyl, a 3-7C cycloalkyl, a halogen, a 2-6C alkenyl or cyano; X1is -O- or NR10-(R10is H, a 1-6C alkyl or a 3-7C cycloalkyl); R1, R3, R4, R5, R6, R7, R8, R9, ring C, l and m are each defined in the specification, provided that a case in which ring C is a 6-14C aryl, a heterocyclic or a 3-7C cycloaryl, and R8and R9are each -CON(R18)(R19) (R18and R19are each defined in the specification) or -COO(R20) (R20is defined in the specification) is not included] or its pharmaceutically acceptable salt is provided. COPYRIGHT: (C)2005,JPO&NCIPI</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2005</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDB0DQ5xDVJw9vcN8A_1c1FwBOIAD8cgX0dn19AQT2dHH4XQYFcFfzeFEA9XhWBHX1ceBta0xJziVF4ozc2g5OYa4uyhm1qQH59aXJCYnJqXWhLvFWBkYGBqZGRgaGzsaEyUIgCAQCaX</recordid><startdate>20050818</startdate><enddate>20050818</enddate><creator>TANIGUCHI HISAO</creator><creator>HAGIWARA ATSUSHI</creator><creator>MADONO KIYONARI</creator><creator>OE YASUHIRO</creator><creator>WATANABE SHIZUE</creator><creator>IKENOUE HIROSHI</creator><creator>KAWAI TAKASHI</creator><creator>KOTANI NAOYA</creator><scope>EVB</scope></search><sort><creationdate>20050818</creationdate><title>ESTER COMPOUND AND PHARMACEUTICAL USE OF THE SAME</title><author>TANIGUCHI HISAO ; HAGIWARA ATSUSHI ; MADONO KIYONARI ; OE YASUHIRO ; WATANABE SHIZUE ; IKENOUE HIROSHI ; KAWAI TAKASHI ; KOTANI NAOYA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2005220133A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2005</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>TANIGUCHI HISAO</creatorcontrib><creatorcontrib>HAGIWARA ATSUSHI</creatorcontrib><creatorcontrib>MADONO KIYONARI</creatorcontrib><creatorcontrib>OE YASUHIRO</creatorcontrib><creatorcontrib>WATANABE SHIZUE</creatorcontrib><creatorcontrib>IKENOUE HIROSHI</creatorcontrib><creatorcontrib>KAWAI TAKASHI</creatorcontrib><creatorcontrib>KOTANI NAOYA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TANIGUCHI HISAO</au><au>HAGIWARA ATSUSHI</au><au>MADONO KIYONARI</au><au>OE YASUHIRO</au><au>WATANABE SHIZUE</au><au>IKENOUE HIROSHI</au><au>KAWAI TAKASHI</au><au>KOTANI NAOYA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ESTER COMPOUND AND PHARMACEUTICAL USE OF THE SAME</title><date>2005-08-18</date><risdate>2005</risdate><abstract>PROBLEM TO BE SOLVED: To provide a hyperlipemia treating agent capable of inhibiting selectively a microsomal triglyceride transfer protein (MTP) in the small bowel, without acting substantially on the MTP in the liver, nor producing an adverse effect, such as fatty liver. SOLUTION: An ester compound expressed by general formula (1') [R2', R2"are each H, a 1-6C (halo)alkyl, a 1-6C alkoxy, a 1-6C acyl, a 3-7C cycloalkyl, a halogen, a 2-6C alkenyl or cyano; X1is -O- or NR10-(R10is H, a 1-6C alkyl or a 3-7C cycloalkyl); R1, R3, R4, R5, R6, R7, R8, R9, ring C, l and m are each defined in the specification, provided that a case in which ring C is a 6-14C aryl, a heterocyclic or a 3-7C cycloaryl, and R8and R9are each -CON(R18)(R19) (R18and R19are each defined in the specification) or -COO(R20) (R20is defined in the specification) is not included] or its pharmaceutically acceptable salt is provided. COPYRIGHT: (C)2005,JPO&NCIPI</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_JP2005220133A |
| source | esp@cenet |
| subjects | ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | ESTER COMPOUND AND PHARMACEUTICAL USE OF THE SAME |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T14%3A09%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TANIGUCHI%20HISAO&rft.date=2005-08-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2005220133A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |